Academic bullying is a serious issue that affects all disciplines and people of all levels of experience. To create a truly safe, productive, and vibrant environment in academia requires coordinated and collaborative input as well as the action of a variety of stakeholders, including scholarly communities, funding agencies, and institutions. This talk will focus on a framework of integrated responding, in which stakeholders as responsible and response-able parties could proactively collaborate and coordinate to reduce the incidence and consequences of academic bullying while at the same time building constructive academic cultures. The outcome of such a framework would be to create novel entities and actions that accelerate successful responses to academic bullying.

In this webinar, the ALBA Network & World Women in Neuroscience partner to address equity, inclusion & diversity issues across the Sub-Saharan African neuroscience community. The panel discussion will explore the challenges and biases faced by African neuroscientists while establishing their careers - focusing on a lack of mentoring and networking but also on the difficulties to raise funding - as well as display the strengths present in the region, which can be exploited to find solutions. Registration is free but required: https://www.alba.network/alba-wwn-webinar-africa

Dr. Ryan C.N. D’Arcy is a Canadian neuroscientist, researcher, innovator and entrepreneur. Dr. D'Arcy co-founded HealthTech Connex Inc. and serves as President and Chief Scientific Officer. HealthTech Connex translates neuroscience advances into health technology breakthroughs. D'Arcy is most known for coining the term "brain vital signs" and for leading the research and development of the brain vital signs framework. Dr. D’Arcy also holds a BC Leadership Chair in Medical Technology, is a full Professor at Simon Fraser University, and a member of the DM Centre for Brain Health at the University of British Columbia. He has published more than 260 academic works, attracted more than $85 Million CAD in competitive research and innovation funding, and been recognized through numerous awards and distinctions. Please join us for an exciting virtual talk with Dr. D'Arcy who will speak on some of the current research he is involved in, how he is translating this research into real-life applications, and the development of HealthTech Connects Inc.

Atherosclerosis is the underlying cause of major cardiovascular events, including heart attack and stroke. The build-up of plaque in coronary arteries can be a major risk for events, but risk is significantly higher in patients with vulnerable rather than stable plaque. Diagnostic imaging of vulnerable plaque is extremely useful for both stratifying patient risk and for determining effectiveness of experimental intervention in reducing cardiovascular risk. In the preclinical setting, being able to distinguish between stable and vulnerable plaque development and pair this with biochemical measures is critical for identification of new experimental candidates. In this webinar, Professor Stephen Nicholls and Dr Kristen Bubb from the Victorian Heart Institute will discuss the benefits of being able to visualise vulnerable plaque for both clinical and preclinical research. Professor Stephen Nicholls is a clinician-researcher and the Head of the Victorian Heart Institute. He is the lead investigator on multiple large, international, cardiovascular outcomes trials. He has attracted over $100 million in direct research funding and published more than 400 peer-reviewed manuscripts. He is focused on both therapeutic intervention to reduce vascular inflammation and lipid accumulation and precision medicine approaches to prevent cardiovascular mortality. Dr Kristen Bubb is a biomedical researcher and Group Leader within the Monash Biomedicine Discovery Institute Cardiovascular Program and Victorian Heart Institute. She focuses on preclinical/translational research into mechanisms underlying vascular pathologies including atherosclerosis and endothelium-driven hypertension within specific vascular systems, including pulmonary and pregnancy-induced. She has published >30 high impact papers in leading cardiovascular journals and attracted category 1&2 funding of >$750,000.

Have a great idea involving AI? Want to launch your own business? It takes many iterations before an idea becomes a startup. Lots of coffee, heartache, and git reverts fuel these iterations. We have learned a lot from Cape AI's own incubated startup, Moonshop, Africa's first autonomous microstore. Watch the demo here: https://www.youtube.com/watch?v=odX6kxhLFC4 Attend our virtual roadshow event to hear lightning talks on creating proofs of concept, failing fast, funding models, selecting and growing a team, finding customers/clients, and building your brand. Afterwards, there will be a short break, then a panel discussion where members of the Cape AI team will answer questions from the audience.

Human vision relies on rapid eye movements (saccades) 2-3 times every second to bring peripheral targets to central foveal vision for high resolution inspection. This rapid sampling of the world defines the perception-action cycle of natural vision and profoundly impacts our perception. Marmosets have similar visual processing and eye movements as humans, including a fovea that supports high-acuity central vision. Here, I present a novel approach developed in my laboratory for investigating the neural mechanisms of visual processing using naturalistic free viewing and simple target foraging paradigms. First, we establish that it is possible to map receptive fields in the marmoset with high precision in visual areas V1 and MT without constraints on fixation of the eyes. Instead, we use an off-line correction for eye position during foraging combined with high resolution eye tracking. This approach allows us to simultaneously map receptive fields, even at the precision of foveal V1 neurons, while also assessing the impact of eye movements on the visual information encoded. We find that the visual information encoded by neurons varies dramatically across the saccade to fixation cycle, with most information localized to brief post-saccadic transients. In a second study we examined if target selection prior to saccades can predictively influence how foveal visual information is subsequently processed in post-saccadic transients. Because every saccade brings a target to the fovea for detailed inspection, we hypothesized that predictive mechanisms might prime foveal populations to process the target. Using neural decoding from laminar arrays placed in foveal regions of area MT, we find that the direction of motion for a fixated target can be predictively read out from foveal activity even before its post-saccadic arrival. These findings highlight the dynamic and predictive nature of visual processing during eye movements and the utility of the marmoset as a model of active vision. Funding sources: NIH EY030998 to JM, Life Sciences Fellowship to JY

Meg was awarded funding to look into how the coronavirus pandemic has affected children's mental health and wellbeing.

This webinar is mainly focused on “Biomarkers for Addiction Treatment Development: fMRI Drug Cue Reactivity as an Example”. Biomarkers and Biotypes of Drug Addiction: funding opportunities at NIDA, Tanya Ramey (NIDA, US) Neuroimaging-based Biomarker Development for Clinical Trials, Owen Carmicheal (Pennington Biomedical Research Center, USA) ENIGMA-Addiction Cue Reactivity Initiative (ACRI) and Checklist, Hamed Ekhtiari (Laureate Institute for Brain Research, USA) ENIGMA-ACRI Checklist: Participant Characteristics, General fMRI Information, General Task Information, Cue Information, Task-related Assessments, Pre-Post Scanning Consideration (James Prisciandaro, Medical University of South Carolina, USA; Marc Kaufman, McLean Hospital/Harvard Medical School, USA; Anna Zilverstand, University of Minnesota; Torsten Wüstenberg, Charité Medical University Berlin, Germany; Falk Kiefer, University of Heidelberg, Germany; Amy Janes, Harvard Medical School, USA) How to Add fMRI Drug Cue Reactivity to the ENIGMA Consortium: Road Ahead, Hugh Garavan, University of Vermont)